Villanova Investment Management Co LLC Reduces Holdings in Integra LifeSciences Holdings Corporation $IART

Key Points

• Villanova Investment Management Co LLC significantly reduced its holdings in Integra LifeSciences by 57.8%, ending the first quarter with 18,226 shares valued at $401,000.
• In contrast, Assenagon Asset Management increased its stake in Integra LifeSciences by a remarkable 2,418.7%, acquiring nearly 1.8 million shares worth approximately $39.6 million.
• Integra LifeSciences reported a 10.4% increase in revenue year-over-year, topping analysts' expectations with earnings per share of $0.45 for the most recent quarter.

Villanova Investment Management Co LLC lowered its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 57.8% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,226 shares of the life sciences company's stock after selling 24,998 shares during the period. Villanova Investment Management Co LLC's holdings in Integra LifeSciences were worth $401,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of IART. Assenagon Asset Management S.A. raised its stake in Integra LifeSciences by 2,418.7% during the first quarter. Assenagon Asset Management S.A. now owns 1,799,944 shares of the life sciences company's stock worth $39,581,000 after purchasing an additional 1,728,480 shares during the period. Soleus Capital Management L.P. purchased a new position in Integra LifeSciences during the fourth quarter worth approximately $28,940,000. Paradigm Capital Management Inc. NY raised its stake in Integra LifeSciences by 170.3% during the fourth quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company's stock worth $32,457,000 after purchasing an additional 901,600 shares during the period. Wellington Management Group LLP raised its stake in Integra LifeSciences by 10.4% during the first quarter. Wellington Management Group LLP now owns 2,766,125 shares of the life sciences company's stock worth $60,827,000 after purchasing an additional 259,987 shares during the period. Finally, Systematic Financial Management LP raised its stake in Integra LifeSciences by 40.7% during the fourth quarter. Systematic Financial Management LP now owns 860,563 shares of the life sciences company's stock worth $19,518,000 after purchasing an additional 248,817 shares during the period. Hedge funds and other institutional investors own 84.78% of the company's stock.

Integra LifeSciences Trading Down 2.7%

Shares of IART stock traded down $0.41 during mid-day trading on Friday, reaching $15.06. The company's stock had a trading volume of 858,242 shares, compared to its average volume of 1,230,027. The company's 50 day simple moving average is $13.61 and its 200-day simple moving average is $15.48. Integra LifeSciences Holdings Corporation has a 12-month low of $11.06 and a 12-month high of $27.13. The company has a quick ratio of 0.73, a current ratio of 1.23 and a debt-to-equity ratio of 1.18. The firm has a market capitalization of $1.17 billion, a PE ratio of -2.31, a price-to-earnings-growth ratio of 0.87 and a beta of 1.20.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Thursday, July 31st. The life sciences company reported $0.45 EPS for the quarter, beating analysts' consensus estimates of $0.43 by $0.02. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The business had revenue of $415.61 million for the quarter, compared to the consensus estimate of $395.06 million. During the same quarter last year, the firm posted $0.63 EPS. The business's revenue for the quarter was down .6% compared to the same quarter last year. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. On average, research analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.